Technical Analysis for RCUS - Arcus Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 200 DMA Resistance | Bearish | 2.57% | |
| MACD Bullish Centerline Cross | Bullish | 2.57% | |
| Upper Bollinger Band Walk | Strength | 2.57% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 11 hours ago |
| Fell Below Upper Bollinger Band | about 11 hours ago |
| 2x Volume Pace | about 17 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
| 3x Volume Pace | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/07/2024
Arcus Biosciences, Inc. Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Clinical Development Cancer Treatment Cancer Immunotherapy Monoclonal Antibodies Immunotherapies Adenosine Cd73 Pd 1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.47 |
| 52 Week Low | 12.96 |
| Average Volume | 643,510 |
| 200-Day Moving Average | 17.24 |
| 50-Day Moving Average | 16.80 |
| 20-Day Moving Average | 15.72 |
| 10-Day Moving Average | 16.27 |
| Average True Range | 0.98 |
| RSI (14) | 61.83 |
| ADX | 23.73 |
| +DI | 28.63 |
| -DI | 10.50 |
| Chandelier Exit (Long, 3 ATRs) | 15.13 |
| Chandelier Exit (Short, 3 ATRs) | 17.04 |
| Upper Bollinger Bands | 17.37 |
| Lower Bollinger Band | 14.07 |
| Percent B (%b) | 1.06 |
| BandWidth | 20.97 |
| MACD Line | 0.13 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.3106 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.77 | ||||
| Resistance 3 (R3) | 18.81 | 18.44 | 18.57 | ||
| Resistance 2 (R2) | 18.44 | 18.13 | 18.42 | 18.50 | |
| Resistance 1 (R1) | 18.00 | 17.94 | 18.22 | 17.96 | 18.43 |
| Pivot Point | 17.63 | 17.63 | 17.74 | 17.61 | 17.63 |
| Support 1 (S1) | 17.18 | 17.31 | 17.40 | 17.14 | 16.67 |
| Support 2 (S2) | 16.81 | 17.12 | 16.79 | 16.60 | |
| Support 3 (S3) | 16.37 | 16.81 | 16.53 | ||
| Support 4 (S4) | 16.33 |
